Faruqi & Faruqi Investigates Claims Against Tvardi Therapeutics Over Disappointing Clinical Trial Results

Faruqi & Faruqi, LLP is investigating claims against Tvardi Therapeutics after the company's shares plummeted over 80% following disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The study did not meet its goals, and preliminary data demonstrated that patients' baseline characteristics were similar across treatment arms, with the exception of percent predicted FVC, which was lower in the placebo-treated patients.